<DOC>
	<DOCNO>NCT00366002</DOCNO>
	<brief_summary>This study evaluate safety , efficacy patient 's perception outcome treatment darifenacin ( 7.5 mg daily ( o.d . ) voluntary increase 15 mg o.d . ) patient OAB dissatisfy prior oxybutynin extend release ( ER ) tolterodine extend release ( ER ) therapy .</brief_summary>
	<brief_title>Patient 's Perception Treatment Outcome With Darifenacin Patients With Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Darifenacin</mesh_term>
	<criteria>• Symptoms OAB least six month prior randomization ≥ 8 micturition average/24 hour ≥ 1 urgency episode average/24 hour without UUIE Patients dissatisfy prior oxybutynin ER tolterodine ER treatment . Patients must either treatment least 1 week 12 month precede study . It require either oxybutynin ER tolterodine ER recent OAB medication take . Patients without prior darifenacin treatment • A mean daily urinary volume &gt; 3000 mL mean volume voided/micturition &gt; 300 mL verify micturition diary two consecutive day prior Baseline Males postvoid residual ( PVR ) urinary volume &gt; 200 mL Baseline Clinically predominant bothersome stress urinary incontinence , determine investigator Urinary retention clinically significant bladder outlet obstruction determine investigator Other protocoldefined inclusion / exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Darifenacin , Overactive Bladder , antimuscarinic , M3 muscarinic receptor antagonist</keyword>
</DOC>